HALO

Business Context and Reporting Period

Company: Halozyme Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Halozyme is a biopharmaceutical company developing products targeting the extracellular matrix using proprietary hyaluronidase enzymes (rHuPH20). The company operates through two marketed products (HYLENEX and Cumulase) and key strategic partnerships with Roche and Baxter. The company has incurred net operating losses since inception and relies on cash reserves and collaboration revenues to fund operations.

Key Financial Metrics

Revenue Composition (Q1 2009): Collaboration agreements accounted for $2.69 million, while product sales contributed $78,207.
Expense Composition (Q1 2009): Research and Development (R&D) expenses were $14.04 million; Selling, General, and Administrative (SG&A) expenses were $3.49 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased by approximately 54% ($966,853) compared to Q1 2008. This was driven primarily by higher revenues under collaboration agreements ($2.69M vs. $1.66M), offset by a decline in product sales ($78k vs. $141k) due to lower Cumulase sales.
• Increased Net Loss: Net loss widened by approximately 48% ($4.77 million) to $14.7 million. This increase was primarily due to a 67% rise in R&D expenses ($5.6 million increase) and a significant drop in interest income ($846k decrease), partially offset by revenue growth.
• R&D Expenses: R&D costs rose to $14.0 million from $8.4 million. Drivers included a $2.6 million increase in outsourced R&D costs (preclinical programs and manufacturing scale-up), a $1.9 million increase in compensation (headcount grew from 69 to 94), and higher clinical trial expenses.
• SG&A Expenses: SG&A decreased by 16% ($671,000) to $3.5 million, largely due to a reduction in corporate legal expenses following an arbitration settlement in the prior year.
• Liquidity: Cash balances decreased by $1.65 million during the quarter. However, net cash used in operating activities improved (decreased) by $1.7 million compared to the prior year, aided by the collection of approximately $7.0 million in partner receivables.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Management anticipates a total net cash burn of approximately $30.0 to $35.0 million for the full year 2009.
• Current cash reserves ($62.1 million) are expected to fund operations for at least the next 12 months.
• Product sales are expected to increase in future periods following the anticipated launch of HYLENEX in the fourth quarter of 2009.
• The company maintains a universal shelf registration statement allowing for the sale of up to $50.0 million in equity or debt securities.

• The company is reallocating resources from the Chemophase program to higher priority programs (Insulin-PH20 and PEGPH20).
• Phase II clinical trials for Insulin-PH20 are underway, with results expected in June 2009.
• Phase I trials for PEGPH20 were initiated in Q1 2009.

• Profitability: The company has never been profitable and expects to incur significant operating losses for the foreseeable future.
• Capital Needs: There is no assurance that additional financing will be available on favorable terms if needed beyond the current 12-month runway.
• Partnership Dependence: Significant revenue and future milestones depend on the performance of partners (Roche and Baxter). Termination or failure to perform by partners would materially harm the business.
• Manufacturing: The company relies entirely on third-party contract manufacturers (Avid Bioservices and Cook Pharmica) for API production. Delays or failures in scaling up production could disrupt clinical trials and commercialization.
• Regulatory Approval: Future revenues depend on obtaining FDA approval for product candidates, which is uncertain and costly.

Key Facts for Investor Verification

• Cash Runway: Verify if the $62.1 million cash balance is sufficient to cover the projected $30-35 million annual burn rate given the current pace of R&D spending.
• Partnership Milestones: Monitor the status of Roche's election of targets and Baxter's HYLENEX launch timeline, as these drive future revenue recognition.
• Manufacturing Scale-Up: Confirm the progress of the technology transfer and scale-up of rHuPH20 production at Cook Pharmica to meet Roche partnership obligations.
• Clinical Trial Results: Track the upcoming June 2009 data release for the Insulin-PH20 Phase II trial, which is critical for the proprietary pipeline.
• Share Dilution: Note the existence of approximately 1.9 million outstanding warrants and 8.1 million stock options that could dilute existing shareholders upon exercise.